Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

(2013) Michael E. Abram et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

(2012) Carolina Garrido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo

(2012) S. Fransen et al.   JOURNAL OF VIROLOGY

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations

(2012) Mark A. Winters et al.   PLoS One

The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy

(2012) Frauke Christ et al.   VIROLOGY

The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

(2012) Matthias Götte   Current Opinion in Virology

Switching between raltegravir resistance pathways analyzed by deep sequencing

(2011) Rithun Mukherjee et al.   AIDS

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143

(2011) Mathieu Métifiot et al.   AIDS

Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A

(2011) S. Reigadas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

(2011) Jose-Luis Blanco et al.   JOURNAL OF INFECTIOUS DISEASES

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

(2010) D. da Silva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir

(2010) Filippo Canducci et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Retroviral intasome assembly and inhibition of DNA strand transfer

(2010) Stephen Hare et al.   NATURE

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

(2010) Sandrine Reigadas et al.   PLoS One

Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo

(2009) O. Delelis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Raltegravir: The First HIV Type 1 Integrase Inhibitor

(2009) Charles Hicks et al.   CLINICAL INFECTIOUS DISEASES

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

(2009) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

(2009) O. Delelis et al.   NUCLEIC ACIDS RESEARCH

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE